CCL2 and leukemia: MCL has been described to show anti-inflammatory activity and reduces LPS-stimulated synthesis of interferon β (IFN-β), tumor necrosis factor-alpha (TNF-α), monocyte chemotactic protein 1 (MCP-1), Interleukin 6 (IL-6), Interleukin 10 (IL-10), and IFN-β in dendritic cells, Monocyte/macrophage cell line (RAW 264.7), human monocytic cell, human CD14+ monocytes THP-1 (leukemia cell line) and primary peritoneal macrophages [51].